Blog

$Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research$

Photo of Ira Pastan from federalnewsnetwork.com

Sep 26, 2024, 11:19

Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).

As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.

cancer cancer awareness Cancer research FDA fight against cancer Global fight against cancer Hairy Cell Leukemia HCL Ira Pastan NCI NCI Center for Cancer Research OncoDaily Oncology

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage